aExclusions are ordered by frequency rather than actual sequence applied.
bExcluded from Cox proportional hazards models because of missing data on hospital characteristics and National Institutes of Health Stroke Scale score.
The number of observations was 61 426 for all-cause mortality and 55 612 for readmission outcomes. The difference between these observations represents the number of deaths during the index hospitalization.
aOf these patients, approximately 42% experienced these outcomes within 30 days.
bIncludes transient ischemic attack, ischemic and hemorrhagic stroke, carotid endarterectomy or stenting. Excludes direct complications of index stroke.
eFigure. Spline plots of one-year outcomes in relationship to door-to-needle times
eTable 1. Patient and hospital characteristics by door-to-needle times of 45 minutes and 60 minutes
eTable 2. Comparison of patient characteristics of included and excluded population
eTable 3. Sensitivity analysis: outcomes at one year by door-to-needle times of 45 minutes and 60 minutes in 2015 and 2016
eTable 4. Outcomes at one year by door-to-needle time in 60-minute increments
eTable 5. Outcomes at one year by door-to-needle time in 45-minute increments
eTable 6. Sensitivity analysis: outcomes at one year by door-to-needle times in 15-minute increments in 2015 and 2016
Customize your JAMA Network experience by selecting one or more topics from the list below.
Man S, Xian Y, Holmes DN, et al. Association Between Thrombolytic Door-to-Needle Time and 1-Year Mortality and Readmission in Patients With Acute Ischemic Stroke. JAMA. 2020;323(21):2170–2184. doi:10.1001/jama.2020.5697
Is there an association between shorter door-to-needle time with thrombolytic therapy and long-term mortality and hospital readmission in patients with acute ischemic stroke?
In this US retrospective cohort study that included 61 426 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator, longer door-to-needle times (within 90 minutes after hospital arrival) were significantly associated with higher all-cause mortality at 1 year (hazard ratio per 15-minute increase in time, 1.04) and higher likelihood of all-cause readmission at 1 year (hazard ratio per 15-minute increase in time, 1.02).
These findings support efforts to shorten time to thrombolytic therapy.
Earlier administration of intravenous tissue plasminogen activator (tPA) in acute ischemic stroke is associated with reduced mortality by the time of hospital discharge and better functional outcomes at 3 months. However, it remains unclear whether shorter door-to-needle times translate into better long-term outcomes.
To examine whether shorter door-to-needle times with intravenous tPA for acute ischemic stroke are associated with improved long-term outcomes.
Design, Setting, and Participants
This retrospective cohort study included Medicare beneficiaries aged 65 years or older who were treated for acute ischemic stroke with intravenous tPA within 4.5 hours from the time they were last known to be well at Get With The Guidelines–Stroke participating hospitals between January 1, 2006, and December 31, 2016, with 1-year follow-up through December 31, 2017.
Door-to-needle times for intravenous tPA.
Main Outcomes and Measures
The primary outcomes were 1-year all-cause mortality, all-cause readmission, and the composite of all-cause mortality or readmission.
Among the 61 426 patients treated with tPA within 4.5 hours, the median age was 80 years and 43.5% were male. The median door-to-needle time was 65 minutes (interquartile range, 49-88 minutes). The 48 666 patients (79.2%) who were treated with tPA and had door-to-needle times of longer than 45 minutes, compared with those treated within 45 minutes, had significantly higher all-cause mortality (35.0% vs 30.8%, respectively; adjusted HR, 1.13 [95% CI, 1.09-1.18]), higher all-cause readmission (40.8% vs 38.4%; adjusted HR, 1.08 [95% CI, 1.05-1.12]), and higher all-cause mortality or readmission (56.0% vs 52.1%; adjusted HR, 1.09 [95% CI, 1.06-1.12]). The 34 367 patients (55.9%) who were treated with tPA and had door-to-needle times of longer than 60 minutes, compared with those treated within 60 minutes, had significantly higher all-cause mortality (35.8% vs 32.1%, respectively; adjusted hazard ratio [HR], 1.11 [95% CI, 1.07-1.14]), higher all-cause readmission (41.3% vs 39.1%; adjusted HR, 1.07 [95% CI, 1.04-1.10]), and higher all-cause mortality or readmission (56.8% vs 53.1%; adjusted HR, 1.08 [95% CI, 1.05-1.10]). Every 15-minute increase in door-to-needle times was significantly associated with higher all-cause mortality (adjusted HR, 1.04 [95% CI, 1.02-1.05]) within 90 minutes after hospital arrival, but not after 90 minutes (adjusted HR, 1.01 [95% CI, 0.99-1.03]), higher all-cause readmission (adjusted HR, 1.02; 95% CI, 1.01-1.03), and higher all-cause mortality or readmission (adjusted HR, 1.02 [95% CI, 1.01-1.03]).
Conclusions and Relevance
Among patients aged 65 years or older with acute ischemic stroke who were treated with tissue plasminogen activator, shorter door-to-needle times were associated with lower all-cause mortality and lower all-cause readmission at 1 year. These findings support efforts to shorten time to thrombolytic therapy.
Quiz Ref IDIntravenous tissue plasminogen activator (tPA), compared with no reperfusion therapy, has been demonstrated in randomized trials to improve 3-month functional outcomes after acute ischemic stroke,1,2 and 1-year to 1.5-year functional outcomes.3,4 Moreover, earlier administration of tPA, compared with later administration, has been shown to be associated with lower risk of in-hospital mortality and hemorrhagic transformation, and better functional outcomes at discharge and at 90 days.1,5,6 However, the relationship between earlier thrombolytic treatment and long-term outcomes has not been well delineated.
For national quality improvement programs of patient care, the relationship between the time interval from hospital arrival (“door”) to the start of the pharmacological infusion (“needle”) and long-term outcomes is of special relevance because door-to-needle time is directly under the control of hospital stroke teams and systems of care. The national quality initiative, Target: Stroke, was launched in January 2010 by the American Heart Association and the American Stroke Association to assist hospitals in reducing door-to-needle times. A series of key best practice strategies were disseminated to hospitals with the goal to achieve door-to-needle times within 60 minutes for at least 50% of patients treated with tPA, which was later raised to 75% of patients, and then the additional goal of door-to-needle times within 45 minutes for at least 50% of patients.7,8
Faster door-to-needle times have been associated with better in-hospital outcomes9; however, their relationship to long-term outcomes at 1 year have not been clearly demonstrated. This study aimed to test the hypothesis that shorter door-to-needle times for tPA are associated with lower 1-year all-cause mortality, all-cause readmission, and the composite of all-cause mortality or readmission among patients hospitalized with acute ischemic stroke.
This US cohort included Medicare beneficiaries aged 65 years or older who were treated with intravenous tPA for acute ischemic stroke at Get With The Guidelines (GWTG)–Stroke participating hospitals between January 1, 2006, and December 31, 2016, with 1-year follow-up through December 31, 2017. Patient clinical data were obtained from the GWTG-Stroke database. The GWTG-Stroke program was launched by the American Heart Association and the American Stroke Association to support continuous quality improvement within hospital systems of care for patients with stroke and transient ischemic attack.
Trained hospital personnel were instructed to collect the data (which included demographics, medical history, stroke onset time, hospital arrival time, in-hospital diagnostic studies, tPA treatment initiation time, and in-hospital outcomes) of consecutive patients treated for acute ischemic stroke or transient ischemic attack by using either prospective clinical identification, retrospective identification via International Classification of Diseases, Ninth Revision, and International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, codes, or a combination of data identification methods.10,11
In an effort to monitor racial/ethnic disparities in stroke care, data on race/ethnicity were recorded by hospital staff from various sources, including patient self-designation, administrative personnel during the registration process, or nursing intake forms.12-14 The data entry tool used supports a multiselect option that includes single racial, multiple racial, and ethnic categories, and a separate data element for Hispanic ethnicity (yes vs no or not documented).12
Data on hospital-level characteristics (eg, the number of beds, academic status, and geographic region) were obtained from the American Hospital Association database. A prior audit showed the overall accuracy of GWTG-Stroke was above 90% for most variables and that time-related performance measures had excellent reliability (κ ≥ 0.75) and door-to-needle times within 60 minutes had good reliability (κ = 0.72).11
Each participating hospital received either human research approval to enroll cases without individual patient consent under the common rule,15 or a waiver of authorization and exemption from subsequent review by its institutional review board. The Duke Clinical Research Institute served as the data analysis center.
Quiz Ref IDTo obtain longitudinal outcomes, the GWTG-Stroke records were linked to Medicare claims files by matching on a series of indirect identifiers, which included hospital admission and discharge dates, identification of the hospital, and the patient’s date of birth and sex as previously reported and validated.16 Medicare is a national health insurance program in the US that covers 98% of adults aged 65 years or older.17 Prior work has demonstrated that patients in the linked database of GWTG-Stroke and Medicare are representative of Medicare patients with ischemic stroke in the US.18
Study entry criteria required patients to (1) have been aged 65 years or older; (2) have a discharge diagnosis of acute ischemic stroke; (3) have been treated with intravenous tPA within 4.5 hours of the time they were last known to be well; (4) have had a documented door-to-needle time; (5) not have been treated with a concomitant therapy with intra-arterial reperfusion techniques; (6) have had the admission be the first for stroke during the study period; and (7) not have been transferred to another acute care hospital, left against medical advice, or without a documented site of discharge disposition (Figure 1).
The prespecified primary outcomes included 1-year all-cause mortality, 1-year all-cause readmission, and the composite of all-cause mortality or readmission at 1 year. One-year cardiovascular readmission was a prespecified secondary outcome and was defined as a readmission with a primary discharge diagnosis of hypertension, coronary artery disease, myocardial infarction, heart failure, abdominal or aortic aneurysm, valvular disease, and cardiac arrhythmia.
Recurrent stroke readmission, a post hoc secondary outcome, was defined as a readmission for transient ischemic attack, ischemic and hemorrhagic stroke, carotid endarterectomy or stenting, but not for direct complications of index stroke. The time to death was measured starting from the index admission date. The time to readmission outcomes was measured starting from the index discharge date.
The Pearson χ2 test was used for categorical variables and the Wilcoxon rank-sum test (Kruskal-Wallis test for >2 categories) for continuous variables to compare patient and hospital characteristics. Standardized differences (calculated as the difference in means or proportions divided by a pooled estimate of the SD × 100 to get a percentage) were used for comparisons between 2 groups.
An absolute standardized difference greater than 10% indicates significant imbalance of a covariate, whereas a standardized difference of 10% or less supports the assumption of balance between treatment groups.19 Door-to-needle time was first analyzed using the prespecified times of within 45 minutes or within 60 minutes vs longer than those targets.7,8 We also evaluated time as continuous variable, as a categorical variable in 15-minute increments using within 30 minutes as the reference group, and in 45-minute and 60-minute increments.
The primary analysis included all patients during the full study period. Patients treated during the 2015-2016 time frame, when endovascular thrombectomy use was increasing, were analyzed in the sensitivity analyses.20
Door-to-needle time associations with outcomes were evaluated for nonlinearity which, if present, was addressed with linear splines. Cox proportional hazards models were used to examine the associations of door-to-needle timeliness and each 1-year outcome with robust variance estimation to account for the clustering of patients within hospitals. The variables used in the risk models were patient-level and hospital-level risk characteristics, which have been shown to be predictive of mortality and have been used in prior GWTG-Stroke analyses.21-26
The patient-level variables included age, sex, race/ethnicity, vascular risk factors (atrial fibrillation or flutter, previous stroke or transient ischemic attack, history of coronary artery disease or myocardial infarction, heart failure, carotid stenosis, diabetes, peripheral artery disease, hypertension, dyslipidemia, and smoking), arrival information (arriving by emergency medical services and during on vs off hours), and stroke severity as measured by the National Institutes of Health Stroke Scale. On hours were defined as 7:00 am to 6:00 pm on any weekday. Off hours were defined as any other time, including evenings, nights, weekends, and national holidays. Prior studies using this prespecified time cutoff have shown that presenting during off hours was associated with inferior quality of care, inferior intravenous thrombolytic treatment, and in-hospital mortality.22,23
The American Heart Association/American Stroke Association Target: Stroke initiative was accounted for by adjusting for admission time before or after 2010. Hospital characteristics included geographic region, urban or rural hospital location, total number of beds, annual volume of ischemic stroke cases, academic status, and whether or not the site was a certified stroke center. The proportional hazards assumption was assessed using the Schoenfeld residual test and it was met because the P value was > .05 for the correlation between weighted residuals and failure times for door-to-needle times. The absolute risk estimates between door-to-needle time categories were calculated using the direct adjustment method and the whole population was used to compute event estimates as an average of estimates for all data observations.
Continuous variables were evaluated for nonlinearity in relation to the outcomes, which, if present, were addressed with linear splines. Multiple imputation with 10 imputations was used to impute missing data for covariates with the fully conditional specification method to account for possible confounders. If the medical history of a patient was missing, it was assumed that no medical conditions were present. Hospital characteristics and the National Institutes of Health Stroke Scale score were not imputed. The cause-specific hazards model was used to account for the competing risk of mortality for readmissions.27
Cumulative incidence curves were generated to estimate the incidence of each outcome of interest. Differences in mortality and the composite of all-cause mortality or readmission at 1 year were compared using the log-rank test. Differences in all-cause readmission, cardiovascular readmission, and recurrent stroke readmission were compared using the Gray test. In addition, the cumulative incidence rates by door-to-needle time were provided.
All statistical analyses were performed using SAS version 9.4 (SAS Institute Inc). All hypothesis tests were 2-sided and P values < .05 were considered statistically significant. The findings should be interpreted as exploratory given the absence of correction for multiple comparisons.
Patient-level and hospital-level characteristics of the included population by door-to-needle times in 15-minute increments appear in Table 1 and by the door-to-needle times of 45 minutes and 60 minutes in eTable 1 in the Supplement. Among the 61 426 Medicare beneficiaries treated with intravenous tPA within 4.5 hours of the time they were last known to be well at the 1651 GWTG-Stroke participating hospitals, the median age was 80 years, 43.5% were male, 82.0% were non-Hispanic white, 8.7% were non-Hispanic black, 4.0% were Hispanic, and 5.3% were of other race/ethnicity. More patients that arrived during off hours were treated within longer door-to-needle times (40.7% for ≤30 minutes, 45.6% for 31-45 minutes, 50.6% for 46-60 minutes, 53.5% for 61-75 minutes, and 56.3% for >75 minutes; P < .001). Despite having longer onset-to-arrival times, some patients had shorter onset-to-needle and door-to-needle times.
Most patients were treated at teaching hospitals (77.7%) and primary stroke centers (73.2%); 3% were treated at rural hospitals. More patients who were treated at teaching hospitals, but not at primary stroke centers, were treated within shorter door-to-needle times. The median door-to-needle time was 65 minutes, with 5.6% of patients treated with tPA within 30 minutes of hospital arrival, 20.8% within 45 minutes, and 44.1% within 60 minutes. The rates of data missingness for patient-level and hospital-level characteristics were low. The exceptions were missing data for National Institutes of Health Stroke Scale score (n = 3614; 5.9%) and arrival mode (n = 2774; 4.5%). There were no missing outcome data.
There was another cohort of 41 195 patients aged 65 years or older who were treated with tPA within 4.5 hours of symptom onset at GWTG-Stroke hospitals during the study period and who met the entry criteria but were excluded because they could not be matched to Medicare claims file data. Matched and unmatched patients differed substantially by age, race/ethnicity, and regional distribution but not by the other baseline characteristics (eTable 2 in the Supplement). Patients who were included in the study were slightly older than those who were excluded (median age, 80 years vs 78 years; standardized difference, 15.87). There were more non-Hispanic white patients who were included vs excluded (82.0% vs 69.7%, respectively) and fewer non-Hispanic black patients who were included vs excluded (8.7% vs 12.2%, respectively) and fewer Hispanic patients (4.0% vs 9.7%) (standardized difference, 30.86). Patients in the West region were underrepresented in the matched cohort compared with the unmatched cohort (18.3% vs 29.3%, respectively).
The door-to-needle time categories of within 45 minutes and within 60 minutes vs longer than these targets and the 1-year outcomes appear in Table 2. The cumulative incidence curves appear in Figure 2. Patients who received tPA after 45 minutes of hospital arrival had worse long-term outcomes than those treated within 45 minutes of hospital arrival, including significantly higher all-cause mortality (35.0% vs 30.8%, respectively; adjusted hazard ratio [HR], 1.13 [95% CI, 1.09-1.18]), higher all-cause readmission (40.8% vs 38.4%; adjusted HR, 1.08 [95% CI, 1.05-1.12]), higher all-cause mortality or readmission (56.0% vs 52.1%; adjusted HR, 1.09 [95% CI, 1.06-1.12]), and higher cardiovascular readmission (secondary outcome) (19.8% vs 18.4%; adjusted HR, 1.05 [95% CI, 1.00-1.10]), but not significantly higher recurrent stroke readmission (a post hoc secondary outcome) (9.3% vs 8.8%; adjusted HR, 1.05 [95% CI, 0.98-1.12]).
Patients who received tPA after 60 minutes of hospital arrival vs within 60 minutes of hospital arrival had significantly higher adjusted all-cause mortality (35.8% vs 32.1%, respectively; adjusted HR, 1.11 [95% CI, 1.07-1.14]), higher all-cause readmission (41.3% vs 39.1%; adjusted HR, 1.07 [95% CI, 1.04-1.10]), higher all-cause mortality or readmission (56.8% vs 53.1%; adjusted HR, 1.08 [95% CI, 1.05-1.10]), and higher cardiovascular readmission (secondary outcome) (20.2% vs 18.6%; adjusted HR, 1.06 [95% CI, 1.01-1.10]), but not significantly higher recurrent stroke readmission (a post hoc secondary outcome) (9.3% vs 8.9%; adjusted HR, 1.03 [95% CI, 0.97-1.09]).
The majority of associations between the door-to-needle times and the outcomes remained statistically significant in a sensitivity analysis limited to patients treated during 2015 and 2016. However, the association between door-to-needle time treatment within 60 minutes and the secondary outcome of cardiovascular readmission was no longer statistically significant (eTable 3 in the Supplement).
The outcomes by door-to-needle times in 45-minute and 60-minute increments appear in eTable 4 and eTable 5 in the Supplement. The absolute differences in outcomes increased with longer door-to-needle times. The cumulative incidence curves showed that approximately 42% of the deaths or readmissions occurred within 30 days.
Long-term outcomes by door-to-needle times in 15-minute increments appear in Table 3, along with the absolute differences and the unadjusted and adjusted HRs from the Cox proportional hazard models. The spline plots in the eFigure in the Supplement graphically illustrate nonlinear associations of door-to-needle times with 1-year mortality, cardiovascular readmission, and recurrent stroke readmission.
Every 15-minute increase in door-to-needle times was significantly associated with higher all-cause mortality (adjusted HR, 1.04 [95% CI, 1.02-1.05] for door-to-needle time within 90 minutes of arrival, which is a cut point derived from the spline plot). However, this association did not persist beyond 90 minutes of hospital arrival. Every 15-minute increase in door-to-needle times was significantly associated with higher all-cause readmission (adjusted HR, 1.02 [95% CI, 1.01-1.03]) and higher all-cause mortality or readmission (adjusted HR, 1.02 [95% CI, 1.01-1.03]). Every 15-minute increase in door-to-needle times after 60 minutes of hospital arrival was significantly associated with higher cardiovascular readmission (secondary outcome) (adjusted HR, 1.02 [95% CI, 1.01-1.04]) and higher stroke readmission (a post hoc secondary outcome) (adjusted HR, 1.02 [95% CI, 1.00-1.04]); however, these associations were not statistically significant for the door-to-needle times within 60 minutes of hospital arrival.
The sensitivity analysis of patients treated during 2015 and 2016 confirmed the associations with the outcomes during the most contemporary period (eTable 6 in the Supplement).
Quiz Ref IDThis nationwide study of older US patients treated with intravenous tPA for acute ischemic stroke in GWTG-Stroke hospitals demonstrated that shorter door-to-needle times for tPA administration were significantly associated with better long-term outcomes, including lower 1-year all-cause mortality, 1-year all-cause readmission, and the composite of all-cause mortality or readmission at 1 year.
Quiz Ref IDPatients who received intravenous tPA with door-to-needle times within 45 minutes had the lowest mortality and readmission rates, followed by door-to-needle times within 60 minutes. When patients were stratified by door-to-needle times that were within 45 minutes or 60 minutes, shorter door-to-needle times were consistently associated with better outcomes, suggesting that these findings were not just the result of an outlier association.
Every 15-minute increase in door-to-needle time up to 90 minutes was significantly associated with worse 1-year outcomes. However, a door-to-needle time within 30 minutes was not significantly associated with even better outcomes. Overall, these findings further support local and national efforts for improving door-to-needle times for thrombolytic therapy.7-9
The Target: Stroke initiative was launched in 2010 to assist hospitals in providing tPA in a timely fashion.7,8 As a result, the proportion of tPA administered within 60 minutes increased from 26.5% during the preintervention period to 41.3% during the postintervention period.9 The lower rates of mortality and readmission associated with shorter door-to-needle times in the current study support calls for continuous implementation of these strategies to reduce delay in tPA administration to parallel the success that has been achieved with shorter door-to-balloon times for percutaneous coronary intervention.28,29
These data are consonant with and extend the results of prior studies. The 2 randomized trials that have assessed long-term outcomes found that allocation to intravenous tPA compared with control reduced disability 1 to 1.5 years after stroke.3,4 In contrast, lower long-term mortality rates with intravenous tPA did not reach statistical significance.3,4 However, the power of these trials to probe for mortality effects was limited by modest sample sizes. The current study, an order of magnitude larger in size, has substantially more power and found statistically significant lower long-term mortality associated with faster intravenous thrombolytic treatment.
A prior study of the GWTG-Stroke registry found that faster onset-to-treatment time with intravenous tPA was associated with improved short-term in-hospital outcomes, including lower in-hospital mortality, lower symptomatic intracranial hemorrhage, and higher likelihood of independent ambulation.6 However, that study did not investigate the association of door-to-needle times with postdischarge outcomes.
Quiz Ref IDThe current study found that accelerated door-to-needle times, specifically within 45 minutes and 60 minutes, were significantly associated with better outcomes including 1-year all-cause mortality, 1-year all-cause readmission, the composite of all-cause mortality or readmission at 1 year, and cardiovascular readmission through 1 year. It is possible that better neurological function after discharge and at 3 months with shorter door-to-needle times have enabled physical activity and a healthier lifestyle resulting in lower cardiovascular events and readmissions.1,5,6,30,31
A door-to-needle time within 30 minutes was not associated with even better outcomes. This lack of association needs to be further investigated, although the analyses may be underpowered for this group (5.6% of total patients). Door-to-needle times were not consistently associated with recurrent stroke readmission, which is in line with trial results finding no effect of tPA administration on stroke recurrence.32
This study has several limitations. First, data on patient characteristics and treatment time intervals were manually recorded and self-reported by the participating hospitals, although prior quality audits of GWTG-Stroke data showed high concordance rates with source documentation.11
Second, to obtain long-term outcomes, this study included fee-for-service Medicare beneficiaries aged 65 years or older who were treated at GWTG-Stroke participating hospitals, with complete data linked in these 2 databases. Previous work has demonstrated that patients in the database that links GWTG-Stroke and Medicare data are representative of the national Medicare population with ischemic stroke.18 However, the results may not be applicable to patients who experience stroke at a younger age.
Third, a prior study of GWTG-Stroke showed that 3.5% of tPA treatments were given to patients who were later classified as not having had an acute ischemic stroke.33 Patients with stroke mimic events were excluded from the current study.
Fourth, 8195 patients (13%) were excluded from the matched population because of missing data on disposition, onset-to-treatment time, or door-to-needle time, which may generate selection bias.
Fifth, rural and minority populations and the West region were underrepresented, which may affect the generalizability of the results.
Sixth, although the outcome analyses adjusted for multiple patient-level and hospital-level baseline characteristics, there might be residual measured and unmeasured confounding including hospital resources that may influence door-to-needle times and outcomes.
Seventh, cost information and other patient-centered outcomes, including quality-of-life and functional outcomes, were not examined.
Eighth, the modest association should be taken into consideration when interpreting the clinical relevance, not merely the statistical significance.
Ninth, the study was limited to patients treated with intravenous tPA within 4.5 hours of the time they were last known to be well and may not be applicable to thrombolytic therapy for stroke with unknown time of symptom onset or stroke events at time of waking up. Magnetic resonance imaging or computerized tomography perfusion scans are needed in these cases to determine patient eligibility for treatment as demonstrated in the recent studies.34,35
Tenth, the cause of death was not studied because Medicare files do not contain this information.
Among patients aged 65 years or older with acute ischemic stroke who were treated with tissue plasminogen activator, shorter door-to-needle times were associated with lower all-cause mortality and lower all-cause readmission at 1 year. These findings support efforts to shorten time to thrombolytic therapy.
Corresponding Author: Gregg C. Fonarow, MD, Ahmanson-UCLA Cardiomyopathy Center, UCLA Medical Center, 10833 LeConte Ave, Los Angeles, CA 90095 (email@example.com).
Accepted for Publication: April 9, 2020.
Author Contributions: Dr Fonarow had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Man, Xian, Saver, Fonarow.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Man, Xian.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Xian, Holmes, Matsouaka.
Obtained funding: Fonarow.
Administrative, technical, or material support: Fonarow.
Supervision: Matsouaka, Saver, Fonarow.
Conflict of Interest Disclosures: Dr Xian reported receiving grants from Genentech; and receiving personal fees from Boehringer Ingelheim. Ms Holmes reported receiving personal fees from the American Heart Association. Dr Saver reported receiving research support from the National Institutes of Health and the American Heart Association; receiving contracted hourly payments from Medtronic, Stryker, Cerenovus, and Boehringer Ingelheim; having stock options in Rapid Medical; and being an employee of the University of California, which holds a patent on an endovascular device for stroke. Dr Bhatt disclosed the following relationships—advisory board: Cardax, Cereno Scientific, Elsevier Practice Update Cardiology, Medscape Cardiology, PhaseBio, PLx Pharma, and Regado Biosciences; board of directors: Boston VA Research Institute, Society of Cardiovascular Patient Care, and TobeSoft; chair: American Heart Association Quality Oversight Committee; data monitoring committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St Jude Medical, now Abbott), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo), and Population Health Research Institute; honoraria: American College of Cardiology (ACC) (senior associate editor of Clinical Trials and News and ACC.org; vice chair of ACC accreditation committee), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (editor in chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (editor in chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (guest editor; associate editor), Medtelligence/ReachMD (continuing medical education [CME] steering committees), MJH Life Sciences, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and US national co-leader, funded by Bayer), Slack Publications (chief medical editor, Cardiology Today’s Intervention), Society of Cardiovascular Patient Care (secretary/treasurer), and WebMD (CME steering committees); other: Clinical Cardiology (deputy editor), NCDR-ACTION Registry Steering Committee (chair), VA CART Research and Publications Committee (chair); research funding: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Idorsia, Ironwood, Ischemix, Lexicon, Lilly, Medtronic, Pfizer, PhaseBio, PLx Pharma, Regeneron, Roche, Sanofi Aventis, Synaptic, the Medicines Company, and TobeSoft; royalties: Elsevier (editor, Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease); site co-investigator: Biotronik, Boston Scientific, CSI, St Jude Medical (now Abbott), and Svelte; trustee: American College of Cardiology; and unfunded research: FlowCo, Merck, Novo Nordisk, and Takeda. Dr Schwamm reported serving as the chair of the American Heart Association/American Stroke Association Get With The Guidelines–Stroke work group and the American Stroke Association advisory committee; serving as a stroke systems consultant to the Massachusetts Department of Public Health; serving as a scientific consultant regarding trial design and conduct to Genentech (late window thrombolysis and member of steering committee for TIMELESS); serving as a member of data and safety monitoring boards for Penumbra (MIND) and Diffusion Pharma (PHAST-TSC); serving as a principal investigator or a member of the national steering committee for Medtronic (Stroke AF) and the National Institute of Neurological Disorders and Stroke (MR WITNESS, StrokeNet Network, and Impact of Telestroke on Patterns of Care and Long-Term Outcomes); and receiving personal fees from Boehringer Ingleheim, Diffusion Pharma, Genentech, Medtronic, and Penumbra. Dr Fonarow reported receiving research support from the Patient-Centered Outcomes Research Institute and the National Institutes of Health; and being an employee of the University of California, which holds a patent on an endovascular device for stroke. No other disclosures were reported.
Funding/Support: The Get With The Guidelines–Stroke (GWTG-Stroke) program is provided by the American Heart Association/American Stroke Association. GWTG-Stroke is sponsored, in part, by Novartis, Boehringer Ingelheim Lilly, Novo Nordisk, Sanofi, AstraZeneca, and Bayer.
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Disclaimer: Dr Saver is Associate Editor of JAMA and Dr Fonarow is Associate Editor of JAMA Cardiology, but neither was not involved in any of the decisions regarding review of the manuscript or its acceptance.
Create a personal account or sign in to: